Idasanutlin, a potent and selective inhibitor of MDM2, effectively inhibits the protein–protein interactions between MDM2‐p53 and is currently being evaluated in 17 different clinical trials for the treatment of acute myeloid leukemia, neuroblastoma, and estrogen receptor‐positive breast cancer.30 This evidence concerns the gene MDM2 and acute myeloid leukemia.